Browse
Submit Data
Databases
API
Help

Dataset Information

390 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics analysis of cystic fluid from human cystic papillary thyroid carcinoma

ABSTRACT: Here we have performed quantitative and qualitative profiling of the proteome of cystic fluid from human cystic papillary thyroid carcinoma with the aim to identify specific proteins and pathways involved in cystic fluid from human cystic papillary carcinoma, as well as possible diagnostic markers.

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Thyroid Nodule, Epithelial Cell Of Thyroid Gland

DISEASE(S): Papillary Thyroid Carcinoma

SUBMITTER: Maria Pernemalm

LAB HEAD: Janne Lehtiö

PROVIDER: PXD000996 | Pride | 2015-05-20

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	HJ_HE_Andrii_121019_EXP1_Fr01-72.msf	Msf
	HJ_HE_Andrii_121019_EXP1_Fr01-72.pep.xml	Pepxml
	HJ_HE_Andrii_121019_EXP1_Fr01-72.prot.xml	Xml
	HJ_HE_Andrii_121019_EXP1_Fr01.raw	Raw
	HJ_HE_Andrii_121019_EXP1_Fr02.raw	Raw

Items per page:

1 - 5 of 152

Publications

Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions.

Dinets Andrii A Pernemalm Maria M Kjellin Hanna H Sviatoha Vitalijs V Sofiadis Anastasios A Juhlin C Christofer CC Zedenius Jan J Larsson Catharina C Lehtiö Janne J Höög Anders A

PloS one 20150515 5

Cystic papillary thyroid carcinoma (cPTC) is a subgroup of PTC presenting a diagnostic challenge at fine needle aspiration biopsy (FNAB). To further investigate this entity we aimed to characterize protein profiles of cyst fluids from cPTC and benign thyroid cystic lesions. In total, 20 cPTCs and 56 benign thyroid cystic lesions were studied. Profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed on cyst fluids from a subset of cases after depletion, and selected pr ...[more]

PMID: 25978681

Similar Datasets

LC-MS/MS analysis of human thyroid cystic fluid and thyroid cancer cell secreted proteins

Project description:Thyroid ultrasound and ultrasound-guided fine-needle aspiration (USG/FNA) biopsy are currently used for diagnosing papillary thyroid carcinoma (PTC), but their detection limit could be improved by combining other biomarkers. To discover novel PTC biomarkers, we herein applied a GeLC-MS/MS strategy to analyze the proteome profiles of serum-abundant-protein-depleted FNA cystic fluid from benign and PTC patients, as well as two PTC cell line secretomes. From them, we identified 346, 488, and 2105 proteins, respectively. Comparative analysis revealed that 191 proteins were detected in the PTC but not the benign cystic fluid samples, and thus may represent potential PTC biomarkers. Among these proteins, 101 were detected in the PTC cell line secretomes, and seven of them (NPC2, CTSC, AGRN, GPNMB, DPP4, ERAP2, and SH3BGRL3) were reported in public PTC transcriptome datasets as having 4681 elevated mRNA expression in PTC. Immunoblot analysis confirmed the elevated expression levels of five proteins (NPC2, CTSC, GPNMB, DPP4, and ERAP2) in PTC versus benign cystic fluids. Immunohistochemical studies from near 100 pairs of PTC tissue and their adjacent non-tumor counterparts further showed that AGRN (n = 98), CTSC (n = 99), ERAP2 (n = 98) and GPNMB (n = 100) were significantly (p<0.05) overexpressed in PTC and higher expression levels of AGRN and CTSC were also significantly associated with metastasis and poor prognosis of PTC patients. Collectively, our results indicate that an integrated analysis of FNA cystic fluid proteome, cancer cell secretome and tissue transcriptome datasets represents a useful strategy for efficiently discovering novel PTC biomarker candidates.

2018-03-21 | PXD007532 | Pride

Sequencing results of FTO overexpressing in papillary thyroid cells [RNA-seq]

Project description:We tried to analyze the effect of FTO on papillary thyroid carcinoma. We constructed a FTO overexpression stable cell line of papillary thyroid carcinoma cells. We performed meRIP-seq sequencing analysis of the FTO overexpression stable transfer cell line to try to assess which genes were changed at the m6A level in papillary thyroid cancer cells by overexpressing FTO.

2022-05-06 | GSE199206 | GEO

Sequencing results of FTO overexpressing in papillary thyroid cells [meRIP-seq]

2022-05-06 | GSE199205 | GEO

RNA-Sequencing of human papillary thyroid carcinomas

Project description:RNA-Sequencing analysis of 18 papillary thyroid carcinoma biopsies and of 4 healthy donors' thyroids. In this analysis we assessed differential gene expression and investigated the mutational landscape in this tumor type. Analysis of gene fusion was also performed, leading to the identification of a novel chimeric transcript, potential driver in tumor initiation. Total RNA isolated from 18 papillary thyroid carcinoma biopsies and 4 healthy donors' thyroids.

2015-05-01 | E-GEOD-64912 | biostudies-arrayexpress

Papillary thyroid cancer proteomics

Project description:Label-free proteomics profiling of 37 paired tumor-normal tissues of papillary thyroid cancer

2024-02-08 | PXD044900 | Pride

MiRNA expression patterns in anaplastic thyroid cancer and papillary thyroid cancer cell lines

Project description:Anaplastic thyroid carcinoma (ATC) is a rare but deadly thyroid cancer. In contrast, papillary thyroid carcinoma (PTC) is common and highly curable. Minimally invasive biomarkers are needed to distinguish ATC and PTC. Here, by small RNA-seq we show the differential expression levels of several miRNAs, which include miR-34a and miR-210 in ATC compared to PTC cell lines.

2022-07-22 | GSE207677 | GEO

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.

Project description:Anaplastic thyroid carcinoma (ATC) has among the worst prognosis of any solid malignancy. The low incidence of the disease has in part precluded systematic clinical trials and tissue collection, and there has been little progress in developing effective therapies. BRAF and TP53 mutations co-occur in a high proportion of ATC, particularly those associated with a precursor papillary thyroid carcinoma (PTC). In order to develop an adult-onset model of BRAF-mutant anaplastic thyroid carcinoma, we generated a novel thyroid-specific CreER transgenic mouse. We utilize a Cre-regulated BrafV600E mouse and a conditional Trp53 allelic series to demonstrate that p53 constrains progression from papillary to anaplastic thyroid carcinoma. Gene expression and immunohistochemical analyses of murine tumors identified the cardinal features of human ATC including loss of differentiation, local invasion, distant metastasis and rapid lethality. We employed small animal ultrasound imaging to monitor autochthonous tumors, and show that treatment with the selective BRAF inhibitor PLX4720 improved survival, but did not lead to tumor regression or suppress signaling through the MAPK pathway. Combination of PLX4720 and the MEK inhibitor PD0325901 more completely suppressed MAPK pathway activation in mouse and human ATC cell lines, and improved the structural response and survival of ATC-bearing animals. This model expands the limited repertoire of autochthonous models of clinically aggressive thyroid cancer, and these data suggest that small molecule MAPK pathway inhibitors hold clinical promise in the treatment of advanced thyroid carcinoma. Total RNA from five murine papillary thyroid carcinoma (PTC) tumors and five murine anaplastic thyroid carcinoma (ATC) tumors was analyzed.

2014-04-02 | E-GEOD-55933 | biostudies-arrayexpress

Dissecting the transcriptomic landscape of the human papillary thyroid carcinoma by single cell RNA-sequencing

Project description:Papillary thyroid carcinoma (PTC) is the most common malignant phenotype of thyroid cancer, with a rapidly increasing number of new cases globally. Multifocality is a common phenomenon in patients with PTC. The tumor microenvironment (TME) plays a pivotal role in cancer progression in papillary thyroid carcinoma (PTC), yet the composition and phenotype of cells within TME in bilateral PTCs are poorly understood.

2022-04-13 | GSE191288 | GEO

Sporadic and Post-Chernobyl Papillary Thyroid Cancers

Project description:We compared the expression profiles of papillary thyroid tumors from the Chernobyl Tissues Bank (CTB) with tumors from French patients with no history of exposure to radiations. Keywords: papillary thyroid cancer vs. patient-matched healthy adjacent thyroid thyroid papillary cancer vs. patient-matched adjacent nontumor thyroid tissues. -14 tumors from France -12 tumors from Ukraine

2007-07-11 | E-GEOD-3950 | biostudies-arrayexpress

Papillary thyroid cancer phosphorylated proteomics

Project description:Phosphorylated proteomics profiling were performed on 37 paired tumor-normal tissues of human papillary thyroid cancer

2024-02-08 | PXD045017 | Pride